Vanguard Group Inc Maxcyte, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Maxcyte, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,347,112 shares of MXCT stock, worth $21 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,347,112
Previous 5,282,108
1.23%
Holding current value
$21 Million
Previous $24.8 Million
9.75%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding MXCT
# of Institutions
126Shares Held
62MCall Options Held
2.4KPut Options Held
2.1K-
Black Rock Inc. New York, NY7.23MShares$28.3 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY6.56MShares$25.7 Million0.98% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.17MShares$24.2 Million0.01% of portfolio
-
Vitruvian Partners LLP5.04MShares$19.8 Million6.7% of portfolio
-
Morgan Stanley New York, NY3.52MShares$13.8 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $399M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...